Category: Science

Books that Paved Way to Darwinian Evolution

(p. C6) “Visions of Science” is, as Mr. Secord acknowledges, “a book about books.” We learn more about typeface size, bindery material, print runs and sales figures of the books than about the authors. We would not glean from this account, for example, how intertwined their lives were: They attended the same parties, discussed science together and reviewed one another’s works. Taken together, the books Mr. Secord features tell a fascinating story, and they paved the way to another that is not featured in Mr. Secord’s account but hovers over the others like Davy’s spirit guide.
In “Origin of Species” (1859), Charles Darwin took the central ideas in these books–that there is a connection between the sciences, that the Earth is much older than previously thought, that God created the world to work by uniform natural law, and that He built lawful change into his original creation–and used them to frame his theory of evolution by natural selection in terms his readers could accept. The success of Darwin–and the books that influenced him–is evidenced by the fact that within two decades of its publication most British scientists and much of the public accepted that species evolved.

For the full review, see:
LAURA J. SNYDER. “Reading from the Book of Life; Darwin’s radical ideas were accepted surprisingly quickly by an English public already steeped in science.” The Wall Street Journal (Sat., April 11, 2015): C6.
(Note: ellipses added.)
(Note: the online version of the review has the date April 10, 2015, and has the title “Science Books That Made Modernity; Darwin’s radical ideas were accepted surprisingly quickly by an English public already steeped in science.”)

The book under review is:
Secord, James A. Visions of Science: Books and Readers at the Dawn of the Victorian Age. Chicago: University of Chicago Press, 2015.

Fongoli Chimps, Where Prey Is Scarce, Show “Respect of Ownership”

(p. A10) The Fongoli chimpanzees live in a mix of savanna and woodlands where prey is not as abundant as in rain forests. There are no red colobus monkeys, and although the chimps do hunt young vervet monkeys and baboons, the much smaller bush babies are their main prey.
Dr. Pruetz argues that less food may have prompted both technological and social innovation, resulting in new ways to hunt and new social interactions as well. Humans evolved in a similar environment, and, as she and her colleagues write in Royal Society Open Science, “tool-assisted hunting could have similarly been important for early hominins.”
. . .
By and large, said Dr. Pruetz, the adult males, which could take away a kill, show a “respect of ownership.” Theft rates are only about 5 percent. The chimps she studies also have more mixed-sex social groups than chimp bands in East Africa.
Travis Pickering, an anthropologist at the University of Wisconsin, said that with less food available it seems that the Fongoli chimps, “have to be more inventive” and that “these hunting weapons even the playing field for non-adults and females.”
Early hominins may have been in a similar situation, he said.

For the full story, see:
JAMES GORMAN. “Hunter Chimps Offer New View on Evolution.” The New York Times (Fri., APRIL 15, 2015): A10.
(Note: ellipsis added.)
(Note: the online version of the story has the date APRIL 14, 2015, and has the title “Chimps That Hunt Offer a New View on Evolution.”)

The academic article discussed above is:
Pruetz, Jill D., Paco Bertolani, K. Boyer Ontl, S. Lindshield, M. Shelley, and E. G. Wessling. “New Evidence on the Tool-Assisted Hunting Exhibited by Chimpanzees (Pan Troglodytes Verus) in a Savannah Habitat at Fongoli, Sénégal.” Royal Society Open Science 2, no. 4 (Weds., April 15, 2015), URL: http://rsos.royalsocietypublishing.org/content/2/4/140507.abstract .

Climate Skeptic Vilified by Mainstream Establishment

ChristyJohnClimateSkeptic2015-03-15.jpg“John Christy, a professor of atmospheric science at the University of Alabama, Huntsville, with the weather data he recorded daily while growing up in Fresno, Calif., in the 1960s.” Source of caption and photo: online version of the NYT article quoted and cited below.

(p. A14) “I detest words like ‘contrarian’ and ‘denier,’ ” he said. “I’m a data-driven climate scientist. Every time I hear that phrase, ‘The science is settled,’ I say I can easily demonstrate that that is false, because this is the climate — right here. The science is not settled.”

Dr. Christy was pointing to a chart comparing seven computer projections of global atmospheric temperatures based on measurements taken by satellites and weather balloons. The projections traced a sharp upward slope; the actual measurements, however, ticked up only slightly.
Such charts — there are others, sometimes less dramatic but more or less accepted by the large majority of climate scientists — are the essence of the divide between that group on one side and Dr. Christy and a handful of other respected scientists on the other.
“Almost anyone would say the temperature rise seen over the last 35 years is less than the latest round of models suggests should have happened,” said Carl Mears, the senior research scientist at Remote Sensing Systems, a California firm that analyzes satellite climate readings.
“Where the disagreement comes is that Dr. Christy says the climate models are worthless and that there must be something wrong with the basic model, whereas there are actually a lot of other possibilities,” Dr. Mears said. Among them, he said, are natural variations in the climate and rising trade winds that have helped funnel atmospheric heat into the ocean.
. . .
. . . , Dr. Christy argues that reining in carbon emissions is both futile and unnecessary, and that money is better spent adapting to what he says will be moderately higher temperatures.
. . .
. . . while his work has been widely published, he has often been vilified by his peers.
. . .
He says he worries that his climate stances are affecting his chances of publishing future research and winning grants. The largest of them, a four-year Department of Energy stipend to investigate discrepancies between climate models and real-world data, expires in September.
“There’s a climate establishment,” Dr. Christy said. “And I’m not in it.”

For the full story, see:
MICHAEL WINES. “Though Scorned by Colleagues, a Climate-Change Skeptic Is Unbowed.” The New York Times (Weds., JULY 16, 2014): A14.
(Note: ellipses added.)
(Note: the online version of the story has the date JULY 15, 2014.)

Successful Billionaire Mathematician Would Have Lost Math Contests, But Was Good at Slow Pondering

(p. D1) James H. Simons likes to play against type. He is a billionaire star of mathematics and private investment who often wins praise for his financial gifts to scientific research and programs to get children hooked on math.
But in his Manhattan office, high atop a Fifth Avenue building in the Flatiron district, he’s quick to tell of his career failings.
He was forgetful. He was demoted. He found out the hard way that he was terrible at programming computers. “I’d keep forgetting the notation,” Dr. Simons said. “I couldn’t write programs to save my life.”
After that, he was fired.
His message is clearly aimed at young people: If I can do it, so can you.
. . .
(p. D2) “I wasn’t the fastest guy in the world,” Dr. Simons said of his youthful math enthusiasms. “I wouldn’t have done well in an Olympiad or a math contest. But I like to ponder. And pondering things, just sort of thinking about it and thinking about it, turns out to be a pretty good approach.”

For the full story, see:
WILLIAM J. BROAD. “Seeker, Doer, Giver, Ponderer; A Billionaire Mathematician’s Life of Ferocious Curiosity.” The New York Times (Tues., JULY 8, 2014): D3.
(Note: ellipsis added.)
(Note: the online version of the story has the date JULY 7, 2014.)

“If You Want to Find Something New, Look for Something New!”

(p. D8) Yves Chauvin, who shared the 2005 Nobel Prize in Chemistry for deciphering a “green chemistry” reaction now used to make pharmaceuticals and plastics more efficiently while generating less hazardous waste, died on Tuesday [January 27, 2015] in Tours, France.
. . .
He confessed that he was not a brilliant student, even in chemistry. “I chose chemistry rather by chance,” he wrote, “because I firmly believed (and still do) that you can become passionately involved in your work, whatever it is.”
Mr. Chauvin graduated from the Lyon School of Industrial Chemistry in 1954. Military service and other circumstances prevented him from pursuing a doctoral degree, which he said he regretted. “I had no training in research as such and as a consequence I am in a sense self-taught,” he wrote in his Nobel Prize lecture.
He worked in industry for a few years before quitting, frustrated by an inability to pursue new ideas. “My motto is more, ‘If you want to find something new, look for something new!’ ” Mr. Chauvin wrote. “There is a certain amount of risk in this attitude, as even the slightest failure tends to be resounding, but you are so happy when you succeed that it is worth taking the risk.”
He found the freedom to choose his research when he joined the French Petroleum Institute in 1960, and it led to his breakthrough on metathesis.
“Like all sciences, chemistry is marked by magic moments,” Mr. Chauvin wrote. “For someone fortunate enough to live such a moment, it is an instant of intense emotion: an immense field of investigation suddenly opens up before you.”

For the full obituary, see:

KENNETH CHANG. “Yves Chauvin, Chemist Sharing Nobel Prize, Dies at 84.” The New York Times (Sat., JAN. 31, 2015): D8.

(Note: ellipsis, and bracketed date, added.)

(Note: the online version of the obituary has the date JAN. 30, 2015.)

Double-Blind Clinical Trials Are NOT the Only Source of Good Evidence

(p. 16) Back in her office, . . . [rheumatologist Jennifer Frankovich] found that the scientific literature had no studies on patients like this to guide her. So she did something unusual: She searched a database of all the lupus patients the hospital had seen over the previous five years, singling out those whose symptoms matched her patient’s, and ran an analysis to see whether they had developed blood clots. “I did some very simple statistics and brought the data to everybody that I had met with that morning,” she says. The change in attitude was striking. “It was very clear, based on the database, that she could be at an increased risk for a clot.”
The girl was given the drug, and she did not develop a clot. “At the end of the day, we don’t know whether it was the right decision,” says Chris Longhurst, a pediatrician and the chief medical information officer at Stanford Children’s Health, who is a colleague of Frankovich’s. But they felt that it was the best they could do with the limited information they had.
A large, costly and time-consuming clinical trial with proper controls might someday prove Frankovich’s hypothesis correct. But large, costly and time-consuming clinical trials are rarely carried out for uncommon complications of this sort. In the absence of such focused research, doctors and scientists are increasingly dipping into enormous troves of data that already exist — namely the aggregated medical records of thousands or even millions of patients to uncover patterns that might help steer care.
. . .
(p. 17) . . . , developing a “learning health system” — one that can incorporate lessons from its own activities in real time — remains tantalizing to researchers. Stefan Thurner, a professor of complexity studies at the Medical University of Vienna, and his researcher, Peter Klimek, are working with a database of millions of people’s health-insurance claims, building networks of relationships among diseases. As they fill in the network with known connections and new ones mined from the data, Thurner and Klimek hope to be able to predict the health of individuals or of a population over time. On the clinical side, Longhurst has been advocating for a button in electronic medical-record software that would allow doctors to run automated searches for patients like theirs when no other sources of information are available.
With time, and with some crucial refinements, this kind of medicine may eventually become mainstream. Frankovich recalls a conversation with an older colleague. “She told me, ‘Research this decade benefits the next decade,’ ” Frankovich says. “That was how it was. But I feel like it doesn’t have to be that way anymore.”

For the full story, see:
VERONIQUE GREENWOOD. “Eureka; Dr. DATA; Can Statistical Analysis Tell Us What Clinical Trials Cannot?” The New York Times Magazine (Sun., OCT. 5, 2014): 16-17.
(Note: ellipses, and bracketed name, added.)
(Note: the online version of the story has the date OCT. 3, 2014, and has the title “Eureka; Can Big Data Tell Us What Clinical Trials Don’t?”)

26 Different Drugs Lengthen Healthy Life Span in Mice

(p. F5) For thousands of years, people have sought to escape or outrun their mortality with potions, pills and elixirs, often blended with heavy doses of hope and will.
In the “Epic of Gilgamesh,” a Mesopotamian king searched for the secret of immortality after the death of his best friend. At least three Chinese emperors in the Tang dynasty died after consuming treatments containing lead and mercury that they hoped would make them immortal. In the late 19th century, a French-American physiologist seemed to have found the elixir of life by injecting the elderly and himself with extracts from animal testicles.
. . .
“By targeting fundamental aging processes, we might be able to delay the major age-related chronic diseases instead of picking them off one at time,” said Dr. James Kirkland, a professor of aging research and head of the Robert and Arlene Kogod Center on Aging at the Mayo Clinic. “For example, we don’t want to have situation where we, say, cure cancer and then people die six months later of Alzheimer’s disease or a stroke. It would be better to delay all of these things together.”
This is where the field known as the biology of aging is moving — to develop drugs that will increase life span and what researchers refer to as health span, the period of life when people are able to live independently and free from disease.
Dr. Kirkland said that at least six drugs had been written up in peer-reviewed journals and that he knew of about 20 others that appear to affect life span or health span in mice. The goal is to see if those benefits can be translated into humans to increase their longevity, “to find interventions that we can use in people that might, say, make a person who’s 90 feel like they’re 60 or a person who’s 70 feel like they’re 40 or 50.”
Other researchers are studying centenarians, seeking to understand whether certain genes have carried them past 100 years old and kept them in good health.

For the full story, see:
TRACEY SAMUELSON. “Science (and Quacks) vs. the Aging Process.” The New York Times (Weds., Nov. 19, 2014): F5.
(Note: ellipsis added.)
(Note: the online version of the story has the date NOV. 18, 2014.)

“You Don’t Reach Serendip by Plotting a Course for It”

(p. 320) As John Barth wrote in The Last Voyage of Somebody the Sailor, “You don’t reach Serendip by plotting a course for it. You have to set out in good faith for elsewhere and lose your bearings serendipitously.”28 The challenge for educational institutions, government policy, research centers, funding agencies, and, by extension, all modern medicine, will be how to encourage scientists to lose their bearings creatively. What they discover may just save our lives!

Source:
Meyers, Morton A. Happy Accidents: Serendipity in Modern Medical Breakthroughs. New York: Arcade Publishing, 2007.
(Note: italics in original.)

Successful Discoverers “Follow the Evidence Wherever It Leads”

(p. 314) Why are particular people able to seize on such opportunities and say, “I’ve stumbled upon a solution. What’s the problem?” Typically, such people are not constrained by an overly focused or dogmatic mindset. In contrast, those with a firmly held set of preconceptions are less likely to be distracted by an unexpected or contradictory observation, and yet it is exactly such things that lead to the blessing of serendipitous discovery.
Serendipitous discoverers have certain traits in common. They have a passionate intensity. They insist on trying to see beyond their own and others’ expectations and resist any pressure that would close off investigation. Successful medical discoverers let nothing stand in their way. They break through, sidestep, or ignore any obstacle or objection to their chosen course, which is simply to follow the evidence wherever it leads. They have no patience with dogma of any kind.
The only things successful discoverers do not dismiss out of hand are contradictory–and perhaps serendipitously valuable–facts. They painstakingly examine every aspect of uncomfortable facts until they understand how they fit with other facts. Far from being cavalier about method, serendipitous discoverers subject their evidence and suppositions to the most rigorous methods they can find. They do not run from uncertainty, but see it as the raw material from which new scientific and medical certainties can be wrought.

Source:
Meyers, Morton A. Happy Accidents: Serendipity in Modern Medical Breakthroughs. New York: Arcade Publishing, 2007.

While Looking for Spotted Fever, He Found the Cause of Lyme Disease

(p. A25) Willy Burgdorfer, a medical entomologist who in 1982 identified the cause of what had been a mysterious affliction, Lyme disease, died on Monday [November 17, 2014] at a hospital in Hamilton, Mont. He was 89.
. . .
In the early 1980s, Dr. Burgdorfer was analyzing deer ticks from Long Island that were suspected to have caused spotted fever when he stumbled on something unexpected under his microscope: spirochetes, disease-causing bacteria shaped like corkscrews. They were located in only one section of the ticks, the so-called midguts. He had studied spirochetes in graduate school.
“Once my eyes focused on these long, snakelike organisms, I recognized what I had seen a million times before: spirochetes,” he said in a 2001 oral history for the National Institutes of Health, which include the National Institute of Allergy and Infectious Diseases.
He had not been working on Lyme disease, but he had spoken with the doctor who helped discover it, Dr. Allen Steere of Yale. After he saw the spirochetes in the Long Island ticks, he quickly realized that the bacteria might also be in the deer ticks believed to be playing a role in Lyme disease in Connecticut and elsewhere, including Long Island.

For the full obituary, see:
WILLIAM YARDLEY. “Willy Burgdorfer, Who Found Bacteria That Cause Lyme Disease, Is Dead at 89.” The New York Times (Thurs., NOV. 20, 2014): A25.
(Note: ellipsis, and bracketed date, added.)
(Note: the online version of the obituary has the date NOV. 19, 2014.)

“Peer Review Institutionalizes Dogmatism by Promoting Orthodoxy”

(p. 305) Peer review institutionalizes dogmatism by promoting orthodoxy. Reviewers prefer applications that mesh with their own perspective on how an issue should be conceptualized, and they favor individuals whom they know or whose reputations have already been established, making it harder for new people to break into the system.6 Indeed, the basic process of peer review demands conformity of thinking and disdains a maverick’s approach. “We can hardly expect a committee,” said the biologist and historian of science, Garrett Hardin, “to acquiesce in the dethronement of tradition. Only an individual can do that.”7 Young investigators get the message loud and clear: Do not challenge existing beliefs and practices.
So enmeshed in the conventional wisdoms of the day, so-called “peers” have again and again failed to appreciate major breakthroughs even when they were staring them in the face. This reality is evidenced by the fact that so many pioneering researchers were inappropriately scheduled to present their findings at undesirable times when few people were in the audience to hear about them.

Source:
Meyers, Morton A. Happy Accidents: Serendipity in Modern Medical Breakthroughs. New York: Arcade Publishing, 2007.